- Home
- CDNS vs REGN Comparison
CDNS vs REGN Comparison
Compare CDNS & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDNS | REGN |
|---|---|---|
| Founded | 1988 | 1988 |
| Country | United States | United States |
| Employees | N/A | 15410 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.0B | 73.2B |
| IPO Year | 1994 | 1995 |
Fundamental Metrics
Financial Performance| Metric | CDNS | REGN |
|---|---|---|
| Price | $346.22 | $637.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 25 |
| Target Price | $375.00 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 2.2M | 855.8K |
| Earning Date | 04-27-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | 5.45 | ★ 8.19 |
| EPS | 1.23 | ★ 6.75 |
| Revenue | $5,296,759,000.00 | ★ $5,872,227,000.00 |
| Revenue This Year | $16.00 | $12.45 |
| Revenue Next Year | $12.39 | $10.13 |
| P/E Ratio | $274.96 | ★ $93.61 |
| Revenue Growth | 14.12 | ★ 20.82 |
| 52 Week Low | $262.75 | $476.49 |
| 52 Week High | $376.35 | $821.11 |
Technical Indicators
Market Signals| Indicator | CDNS | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.85 | 29.55 |
| Support Level | $339.62 | $547.67 |
| Resistance Level | $359.43 | $783.87 |
| Average True Range (ATR) | 9.00 | 18.32 |
| MACD | -2.95 | -7.98 |
| Stochastic Oscillator | 43.24 | 23.57 |
Price Performance
Historical ComparisonAbout CDNS Cadence Design Systems Inc.
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enables system-level analysis and verification solutions.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.